The prevalence of SUDs is rising dramatically, with rates as high as 17 million for alcohol use disorder (AUD) and over 2 million for opioid use disorder (OUD). More than 100 American deaths per day are attributable to OUD alone. Despite available treatments, SUDs remain undertreated, perpetuating poor patient outcomes. This session will examine the latest research and evidence surrounding SUD treatment advances, including differences among oral and depot formulations, efficacy of available options within long-term management, implications on patient adherence, potential for illicit diversion, and associated genetic predilections to treatment response. In addition, as it is common for SUDs to co-exist with psychiatric disorders, evidence-based strategies for addressing concomitant SUD and other psychiatric disorders will be explored.
Supported by an educational grant from Alkermes, Inc.
